SarcoMed USA

Executive Summary

SarcoMed USA is a private biotech company dedicated to developing novel therapies for pulmonary sarcoidosis and other serious respiratory diseases. Founded in 2018 and based in New York, the company's lead asset, SM001 (alidornase/Tigerase), is an inhaled DNase 1 therapy designed to reduce granulomatous inflammation by targeting neutrophil extracellular traps. SM001 has received FDA orphan drug designation for pulmonary sarcoidosis, highlighting the significant unmet need in this rare, chronic inflammatory lung disease. SarcoMed has assembled a team of drug development experts and is advancing SM001 through clinical development. The company represents an intriguing opportunity in the rare respiratory disease space. While pulmonary sarcoidosis lacks approved therapies that address the underlying granulomatous pathology, SM001's novel mechanism of action could offer a differentiated treatment option. Key risks include early-stage clinical data and the need for substantial funding to complete development. However, the orphan drug designation provides regulatory and commercial incentives. SarcoMed's focus on a high unmet medical need and its proprietary approach position it for potential success, though execution and clinical outcomes remain critical.

Upcoming Catalysts (preview)

• Q1 2027Phase 2a clinical trial results for SM00160% success
• Q4 2026Series B financing or strategic partnership50% success
• Q3 2026FDA feedback on Phase 2b trial design80% success